Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

NCT00209989 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT00209989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00209989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
Lead sponsor
Institut Claudius Regaud
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
June 30, 2011
Enrollment
27 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme